The purpose of this study was to assess whether MR contrast-enhancement in healthy stromal tissue of the breast is able to further stratify survival of patients considered to be at high risk according to prognostic models derived from the tumor. In 415 patients with pathology proven unilateral invasive ER+HER2- breast cancer, the contralateral parenchymal enhancement was automatically extracted. Contralateral parenchymal enhancement appears to complement existing prognostic models derived from the tumor. In patients at high risk according to conventional prognostic models or molecular assays, contralateral parenchymal enhancement was able identify a subgroup with a relative good survival.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords